Evidence map›Paper›PMID 39227330›Full record

ArticleJournal of clinical neurology (Seoul, Korea)2024

Predicting the Progression of Mild Cognitive Impairment to Alzheimer's Dementia Using Recurrent Neural Networks With a Series of Neuropsychological Tests.

Chaeyoon Park, Gihun Joo, Minji Roh, Seunghun Shin, Sujin Yum, Na Young Yeo, Sang Won Park, Jae-Won Jang, Hyeonseung Im, Alzheimer's Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Journal of clinical neurology (Seoul, Korea), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Current Clinical Applications of Structural MRI in Neurological Disorders.Journal of clinical neurology (Seoul, Korea) · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Monoclonal Antibodies-A New Horizon in Alzheimer's Treatment.Journal of clinical neurology (Seoul, Korea) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chaeyoon ParkGraduate School of Data Science, Kangwon National University, Chuncheon, Korea.ORCID https://orcid.org/0009-0004-7470-0517
Gihun JooInterdisciplinary Graduate Program in Medical Bigdata Convergence, Kangwon National University, Chuncheon, Korea.ORCID https://orcid.org/0000-0003-4376-5356
Minji RohInterdisciplinary Graduate Program in Medical Bigdata Convergence, Kangwon National University, Chuncheon, Korea.ORCID https://orcid.org/0000-0002-7926-4820
Seunghun ShinInterdisciplinary Graduate Program in Medical Bigdata Convergence, Kangwon National University, Chuncheon, Korea.ORCID https://orcid.org/0009-0009-1574-4452
Sujin YumInterdisciplinary Graduate Program in Medical Bigdata Convergence, Kangwon National University, Chuncheon, Korea.ORCID https://orcid.org/0000-0002-8627-682X
Na Young YeoInterdisciplinary Graduate Program in Medical Bigdata Convergence, Kangwon National University, Chuncheon, Korea.ORCID https://orcid.org/0000-0002-3934-8157
Sang Won ParkDepartment of Neurology, Kangwon National University Hospital, Chuncheon, Korea.ORCID https://orcid.org/0000-0001-9796-2799
Jae-Won JangInterdisciplinary Graduate Program in Medical Bigdata Convergence, Kangwon National University, Chuncheon, Korea.ORCID https://orcid.org/0000-0003-3540-530X
Hyeonseung ImGraduate School of Data Science, Kangwon National University, Chuncheon, Korea.ORCID https://orcid.org/0000-0002-3901-0834
Alzheimer's Disease Neuroimaging Initiative

Funding

Institute for Information and Communications Technology Promotion 2022-0-01196National Research Foundation of Korea 2022RIS-005National Research Foundation of Korea RS-2023-00242528
6 · The paper itself

Abstract

background and purposeThe prevalence of Alzheimer's dementia (AD) is increasing as populations age, causing immense suffering for patients, families, and communities. Unfortunately, no treatments for this neurodegenerative disease have been established. Predicting AD is therefore becoming more important, because early diagnosis is the best way to prevent its onset and delay its progression.

methodsMild cognitive impairment (MCI) is the stage between normal cognition and AD, with large variations in its progression. The disease can be effectively managed by accurately predicting the probability of MCI progressing to AD over several years. In this study we used the Alzheimer's Disease Neuroimaging Initiative dataset to predict the progression of MCI to AD over a 3-year period from baseline. We developed and compared various recurrent neural network (RNN) models to determine the predictive effectiveness of four neuropsychological (NP) tests and magnetic resonance imaging (MRI) data at baseline.

resultsThe experimental results confirmed that the Preclinical Alzheimer's Cognitive Composite score was the most effective of the four NP tests, and that the prediction performance of the NP tests improved over time. Moreover, the gated recurrent unit model exhibited the best performance among the prediction models, with an average area under the receiver operating characteristic curve of 0.916.

conclusionsTimely prediction of progression from MCI to AD can be achieved using a series of NP test results and an RNN, both with and without using the baseline MRI data.

Indexed as

Alzheimer's diseasedementiamild cognitive impairmentneural network modelsneuropsychological tests

Identifiers

PMID39227330
PMCPMC11372213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.